Citations

Clear

20 citation(s) found for "McDonagh, C".

A96-02 Isoflurane or Propofol for Sedation of Mechanically Ventilated Adults in the ICU: Results of the Inspire ICU Trials
Beitler, J R, Boncyk, C, O'Gara, B P, Englert, J A, Sachdev, A, Owens, R L, Baram, M, Chang, S Y, Berra, L, Blank, R D, Kim, C, Tanios, M A, Fort, A, Lubinsky, G, Odish, M F, Eisinger, G J, Santarisi, A, Serra, A L, Leon, J Espinosa, Garcia, I, Arboleda, A de Lima, Olney, S J, Dzierba, A L, Capers, K, Patel, M, Park, P K, Rengel, K, Carr, J R, Hill, N S, Brainard, J, Hudock, K M, Faisal, H, McDonagh, D, Smischney, N J, Mireles-Cabodevila, E, Nates, J L, Knox, D, Faugno, A J, Fuchita, M, Hite, R, Rizk, E, Jabaley, C, Peltan, I D, Yong, C M, Sheppard, K, Pun, B, Sverud, I, Sackey, P, Hughes, C, Investigators, INSPIRE ICU, Jabaley, Craig S. , Jabaley, Craig S , Beitler, Jeremy R. , Boncyk, Christina S. , O’Gara, Brian , Englert, Joshua A. , Sachdev, Alisha , Owens, R.L., Berra, Lorenzo M. , Tanios, Maged A. , Odish, Mazen Faris , Eisinger, Gregory J. , Santarisi, Abeer , Olney, Sara, Dzierba, Amy L. , Park, P.K., Rengel, Kimberly F. , Hill, N S, Hudock, Kristin , Smischney, Nathan J. , Mireles‐Cabodevila, Eduardo , Nates, Joseph L. , Faugno, Anthony J. , Sverud, Ida, Sackey, Peter , Hughes, Christopher G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.4657 Get It

Abstract Introduction Sedation is routinely administered to facilitate comfort and tolerance of life support for critically ill adults dependent on invasive mechanical ventilation. Isoflurane, a widely used anesthetic during surgery, has properties that may also benefit ICU patients requiring continuous sedation. However, efficacy as a sedative and safety in this population is not well established. Methods We conducted two identically designed multicenter randomized trials, INSPIRE ICU1 and INSPIRE ICU2, at hospitals across the US. Ventilator-dependent adults were randomly assigned in a 1.5:1 ratio to receive either inhaled isoflurane or intravenous propofol as the first-line sedative for up to 48 ± 6 hours, targeting a sedation depth between Richmond agitation-sedation scale (RASS) -1 (drowsy) to -4 (responsive only to physical stimuli). Isoflurane was administered via an anesthetic conserving device (Sedaconda ACD-S). In both arms, opioids were permitted at the lowest dose required to achieve freedom from pain. The primary outcome was the percentage of time at target sedation level, assessed as a noninferiority outcome with pre-specified margin of 15%. Secondary outcomes included opioid exposure, wake-up time after end of treatment, time to extubation, and proportion of time with spontaneous breathing effort. Results A total of 470 combined participants were included in the two trials. In each trial, 142 patients were randomly assigned to isoflurane and 93 to propofol. In INSPIRE ICU1, percentage of time within target sedation depth was 77.1 [53.2, 89.9] % with isoflurane and 80.9 [58.2, 96.4] % with propofol (difference -1.5 [-8.9, >99] %; p < 0.01 for noninferiority). In INSPIRE ICU2, percentage of time within target sedation depth was 72.6 [66.4, 78.9] % with isoflurane and 74.5 [67.5, 81.5] % with propofol (difference -1.9 [-9.4, >99] %; p < 0.01 for noninferiority). In both trials, patients assigned to isoflurane received significantly less opioid, measured as fentanyl equivalents, during the treatment period. In INSPIRE ICU2, participants receiving isoflurane were significantly likelier to exhibit spontaneous breathing efforts, but this finding was not replicated in INSPIRE ICU1. There were no significant differences in time to wake-up or time to extubation between groups in either trial. No episodes of malignant hyperthermia or propofol infusion syndrome were reported. Adverse events were comparable in type and frequency between groups. Conclusions In two US multicenter trials, isoflurane was noninferior to propofol for maintaining target sedation depth in adults undergoing invasive ventilation, and was associated with significantly lower opioid exposure. (NCT05327296, NCT05312385) This abstract is funded by: Sedana Medical
Transcobalamin receptor antibodies in autoimmune vitamin B12 central deficiency
Pluvinage, John V. , Ngo, Thomas , Fouassier, Camille , McDonagh, Maura A. , Holmes, Brandon B. , Bartley, Christopher M. , Kondapavulur, Sravani , Hurabielle, Charlotte , Bodansky, Aaron , Pai, Vincent , Aslanpour, Ava , Alvarenga, Bonny D. , Zamecnik, Colin R. , Asencor, Andoni I., Huynh, Thanh Dat , Browne, Weston, Tubati, Asritha , Haney, Michael S. , Douglas, Vanja C. , Louiné, Martineau , Hauser, Stephen L. , Baranzini, Sergio E. , Wells, James A. , Spudich, Serena , Farhadian, Shelli , Ramachandran, Prashanth , Gillum, Leslie A. , Hales, Chadwick M. , Anderson, Mark S. , Smith, Bryan , Nath, Avindra , Green, Ari , Wilson, Michael R. , McDonagh, Maura , Hinman, Sam , Alvarenga, Bonny D , Zorn, Kelsey C , Zamecnik, Colin , Asencor, Andoni I , Huynh, Trung , Tubati, Asritha , Haney, Michael S , Louine, Martineau , Cree, Bruce Ac , Hauser, Stephen L. , Seeley, William , Baranzini, Sergio E , Wells, James A , Spudich, Serena , Farhadian, Shelli , Ramachandran, Prashanth S , Gillum, Leslie , Zikherman, Julie , Anderson, Mark S , Yazdany, Jinoos , Smith, Bryan , Nath, Avindra , Suh, Gina A , Flanagan, E P , Green, Ari J , Green, Ralph , Gelfand, Jeffrey M , DeRisi, Joseph L , Pleasure, Samuel J , Wilson, Michael R , Pluvinage, John V , Bodansky, Aaron , Hinman, Samuel S. , McCann, Adrian , Cree, Bruce , Seeley, William W. , Yazdany, Jinoos , Suh, Gina A. , Flanagan, Eoin P. , Gelfand, Jeffrey M.

Mayo Clinic

Science Translational Medicine | June 26, 2024 | Volume: 16 | Issue: 753 | Pages: No page available

10.1126/scitranslmed.adl3758 | PMID 38924428 Get It

Vitamin B12 is critical for hematopoiesis and myelination. Deficiency can cause neurologic deficits including loss of coordination and cognitive decline. However, diagnosis relies on measurement of vitamin B12 in the blood, which may not accurately reflect the concentration in the brain. Using programmable phage display, we identified an autoantibody targeting the transcobalamin receptor (CD320) in a patient with progressive tremor, ataxia, and scanning speech. Anti-CD320 impaired cellular uptake of cobalamin (B12) in vitro by depleting its target from the cell surface. Despite a normal serum concentration, B12 was nearly undetectable in her cerebrospinal fluid (CSF). Immunosuppressive treatment and high-dose systemic B12 supplementation were associated with increased B12 in the CSF and clinical improvement. Optofluidic screening enabled isolation of a patient-derived monoclonal antibody that impaired B12 transport across an in vitro model of the blood-brain barrier (BBB). Autoantibodies targeting the same epitope of CD320 were identified in seven other patients with neurologic deficits of unknown etiology, 6% of healthy controls, and 21.4% of a cohort of patients with neuropsychiatric lupus. In 132 paired serum and CSF samples, detection of anti-CD320 in the blood predicted B12 deficiency in the brain. However, these individuals did not display any hematologic signs of B12 deficiency despite systemic CD320 impairment. Using a genome-wide CRISPR screen, we found that the low-density lipoprotein receptor serves as an alternative B12 uptake pathway in hematopoietic cells. These findings dissect the tissue specificity of B12 transport and elucidate an autoimmune neurologic condition that may be amenable to immunomodulatory treatment and nutritional supplementation.
Management of cardiac sarcoidosis
Sharma, Rakesh , Metra, Marco , Heidecker, Bettina , Baksi, John, Wicks, Eleanor , Tschöpe, Carsten , Petersen, Steffen E. , Lüscher, Thomas F. , Filippatos, Gerasimos , Metra, Marco , Klingel, Karin , Imazio, Massimo , Petersen, Steffen E , Heidecker, Bettina , Tschöpe, Carsten , Sharma, Rakesh , Kouranos, Vasileios , Cooper, Leslie T. , Ristić, Arsen , Merino, José Luís , Imazio, Massimo , Chillou, Christian de , Kuchynka, Petr , McDonagh, Theresa A.

Mayo Clinic

European Heart Journal | May 22, 2024 | Volume: 45 | Issue: 30 | Pages: 2697-2726

10.1093/eurheartj/ehae356 | PMID 38923509 Get It

Abstract Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a multidisciplinary approach. By integrating clinical information and the results of diagnostic tests, an accurate, validated, and timely diagnosis can be made, while alternative diagnoses can be reasonably excluded. This clinical expert consensus statement reviews the evidence on the management of different CS manifestations and provides advice to practicing clinicians in the field on the role of immunosuppression and the treatment of cardiac complications based on limited published data and the experience of international CS experts. The monitoring and risk stratification of patients with CS is also covered, while controversies and future research needs are explored.
A systematic review on outcome reporting in randomised controlled trials assessing treatment interventions in pregnant women with pregestational diabetes
Kgosidialwa, Oratile , Bogdanet, Delia , Egan, Aoife M. , Newman, Christine , O’Shea, Paula , Biesty, Linda , McDonagh, C, O'Shea, C, Devane, Declan , Dunne, Fidelma , Kgosidialwa, O , Bogdanet, D , Egan, A M , O'Shea, Paula M , Dunne, Fidelma P , Newman, Christine

Mayo Clinic

BJOG: An International Journal of Obstetrics & Gynaecology | July 14, 2021 | Volume: 128 | Issue: 12 | Pages: 1894-1904

10.1111/1471-0528.16842 | PMID 34258852 Get It

BackgroundPregestational diabetes mellitus (PGDM) is associated with adverse pregnancy outcomes. Studies assessing interventions to improve maternal and infant outcomes have increased exponentially over recent years. Several outcomes in this field of maternal diabetes are rare, making it difficult to synthesise evidence.ObjectivesTo collect outcomes reported in studies assessing treatment interventions in pregnant women with PGDM.Search strategyCENTRAL, Web of Science, Medline, CINAHL, Embase and ClinicalTrials.gov from their inception until 27 January 2020.Selection criteriaAny randomised controlled trial assessing treatment interventions in pregnant women with PGDM reported in English.Data collection and analysisTwo independent reviewers assessed the suitability of articles and retrieved the data. Outcomes extracted from the literature were broadly categorised into maternal, fetal/infant or other outcomes by the study advisory group.Main resultsSixty‐seven of the 1475 studies identified fulfilled the inclusion criteria. The median number of outcomes reported per study was 15 (range 1–46). The majority of studies were from North America and Europe. Insulin and metformin were the most commonly investigated pharmacological interventions. Glucose monitoring was the most assessed technological intervention. In all, 131 unique outcomes were extracted: maternal (n = 69), fetal/infant (n = 61) and other (n = 1).ConclusionsOutcome reporting in treatment interventions trials of pregnant women with PGDM is varied, making it difficult to synthesise evidence, especially for rare outcomes. Systems are needed to standardise outcome reporting in future clinical trials and so facilitate evidence synthesis in this area of maternal diabetes.RegistrationThe systematic review was registered prospectively with the International Prospective Register of Systematic Reviews (PROSPERO) database (Registration number CRD42020173549).Tweetable abstractOutcome reporting is heterogeneous in intervention trials of pregnant women with diabetes existing before pregnancy.
A core outcome set for the treatment of pregnant women with pregestational diabetes: an international consensus study
Kgosidialwa, Oratile , Bogdanet, Delia , Egan, Aoife M. , O’Shea, Paula , Newman, Christine , Griffin, Tomás P. , McDonagh, C, O'Shea, C, Carmody, Louise , Cooray, Shamil D. , Anastasiou, E., Wender‐Ożegowska, Ewa, Clarson, Cheril , Spadola, Alexandra, Alvarado, Fernanda , Noctor, Eoin , Dempsey, Eugene , Napoli, Angela , Galjaard, Sander , Loeken, Mary R. , Maresh, M., Gillespie, Paddy , Valk, Harold de, Biesty, Linda , Devane, Declan , Dunne, Fidelma , Kgosidialwa, O , Bogdanet, D , Egan, A M , Cooray, S D , O'Shea, Paula M , Gillespie, Paddy , Dunne, Fidelma P , Crowther, Caroline Anne , Agostini, Andrea , Newman, Christine

Mayo Clinic

BJOG: An International Journal of Obstetrics & Gynaecology | July 4, 2021 | Volume: 128 | Issue: 11 | Pages: 1855-1868

10.1111/1471-0528.16825 | PMID 34218508 Get It

Objective To develop a core outcome set (COS) for randomised controlled trials (RCTs) evaluating the effectiveness of interventions for the treatment of pregnant women with pregestational diabetes mellitus (PGDM). Design A consensus developmental study. Setting International. Population Two hundred and five stakeholders completed the first round. Methods The study consisted of three components. (1) A systematic review of the literature to produce a list of outcomes reported in RCTs assessing the effectiveness of interventions for the treatment of pregnant women with PGDM. (2) A three‐round, online eDelphi survey to prioritise these outcomes by international stakeholders (including healthcare professionals, researchers and women with PGDM). (3) A consensus meeting where stakeholders from each group decided on the final COS. Main outcome measures All outcomes were extracted from the literature. Results We extracted 131 unique outcomes from 67 records meeting the full inclusion criteria. Of the 205 stakeholders who completed the first round, 174/205 (85%) and 165/174 (95%) completed rounds 2 and 3, respectively. Participants at the subsequent consensus meeting chose 19 outcomes for inclusion into the COS: trimester‐specific haemoglobin A1c, maternal weight gain during pregnancy, severe maternal hypoglycaemia, diabetic ketoacidosis, miscarriage, pregnancy‐induced hypertension, pre‐eclampsia, maternal death, birthweight, large for gestational age, small for gestational age, gestational age at birth, preterm birth, mode of birth, shoulder dystocia, neonatal hypoglycaemia, congenital malformations, stillbirth and neonatal death. Conclusions This COS will enable better comparison between RCTs to produce robust evidence synthesis, improve trial reporting and optimise research efficiency in studies assessing treatment of pregnant women with PGDM. Tweetable abstract 165 key stakeholders have developed #Treatment #CoreOutcomes in pregnant women with #diabetes existing before pregnancy.
Estimation of patient skin dose in fluoroscopy: summary of a joint report by AAPM TG357 and EFOMP
Andersson, Jonas , Bednarek, Daniel R. , Boltz, Thomas, Bosmans, Hilde , Gislason‐Lee, Amber J., Granberg, Christoffer, Hellström, Max , Kanal, Kalpana M. , McDonagh, Ed, Paden, Robert G., Pavlicek, William , Khodadadegan, Yasaman, Torresin, A. , Trianni, Annalisa , Zamora, D , Paden, Robert, Bolch, Wesley E.

Mayo Clinic

Medical Physics | April 30, 2021 | Volume: 48 | Issue: 7 | Pages: No page available

10.1002/mp.14910 | PMID 33930183 Get It

BackgroundPhysicians use fixed C‐arm fluoroscopy equipment with many interventional radiological and cardiological procedures. The associated effective dose to a patient is generally considered low risk, as the benefit‐risk ratio is almost certainly highly favorable. However, X‐ray‐induced skin injuries may occur due to high absorbed patient skin doses from complex fluoroscopically guided interventions (FGI). Suitable action levels for patient‐specific follow‐up could improve the clinical practice.There is a need for a refined metric regarding follow‐up of X‐ray‐induced patient injuries and the knowledge gap regarding skin dose‐related patient information from fluoroscopy devices must be filled. The most useful metric to indicate a risk of erythema, epilation or greater skin injury that also includes actionable information is the peak skin dose, that is, the largest dose to a region of skin.Materials and MethodsThe report is based on a comprehensive review of best practices and methods to estimate peak skin dose found in the scientific literature and situates the importance of the Digital Imaging and Communication in Medicine (DICOM) standard detailing pertinent information contained in the Radiation Dose Structured Report (RDSR) and DICOM image headers for FGI devices. Furthermore, the expertise of the task group members and consultants have been used to bridge and discuss different methods and associated available DICOM information for peak skin dose estimation.ResultsThe report contributes an extensive summary and discussion of the current state of the art in estimating peak skin dose with FGI procedures with regard to methodology and DICOM information. Improvements in skin dose estimation efforts with more refined DICOM information are suggested and discussed.ConclusionsThe endeavor of skin dose estimation is greatly aided by the continuing efforts of the scientific medical physics community, the numerous technology enhancements, the dose‐controlling features provided by the FGI device manufacturers, and the emergence and greater availability of the DICOM RDSR. Refined and new dosimetry systems continue to evolve and form the infrastructure for further improvements in accuracy. Dose‐related content and information systems capable of handling big data are emerging for patient dose monitoring and quality assurance tools for large‐scale multihospital enterprises.
Core Outcome Sets for Studies of Diabetes in Pregnancy: A Review
Egan, Aoife M. , Bogdanet, Delia , Biesty, Linda , Kgosidialwa, Oratile , McDonagh, C, O'Shea, C, O’Shea, Paula , Devane, Declan , Dunne, Fidelma , O'Shea, Paula M , Egan, A M , Kgosidialwa, O , Bogdanet, D , Dunne, Fidelma P

Mayo Clinic

Diabetes Care | November 21, 2020 | Volume: 43 | Issue: 12 | Pages: 3129-3135

10.2337/dc20-1621 | PMID 33218980 Get It

Core Outcome Sets (COS) contain an agreed minimum set of outcomes to be measured and reported in all studies in a specific area, with the objective of standardizing outcome reporting. COS may minimize research waste by identifying outcomes important to key stakeholders, allowing for improved evidence synthesis, and facilitating translation of research findings to clinical practice. Over the past 5 years, there has been significant progress in developing COS relevant to studies of diabetes in pregnancy. This review summarizes work in this area, reviews the role of patient and public involvement in COS development, and suggests areas for future research.
Identification of the Molecular Genetic Defect of Patients With Methemoglobin M Kankakee (M-Iwate), 87 (F8) His → Tyr: Evidence for an Electrostatic Model of M Hemoglobin Assembly
Ameri, Afshin, Fairbanks, Virgil F., Yanik, Greg, Mahdi, F., Thibodeau, Stephen N. , Boxer, Laurence A., McDonagh, Kevin T., McCormick, Daniel

Mayo Clinic

Blood | October 14, 2019 | Volume: 94 | Issue: 5 | Pages: 1825-1826

10.1182/blood.v94.5.1825 Get It

AbstractWe determined that the molecular defect of 2 patients with hemoglobin (Hb) M-Kankakee [Hb M-Iwate, 87 (F8) His → Tyr] resides in the 1-globin gene. The proportion of Hb M observed is higher than that predicted for an 1-globin variant. Our evidence suggests that the greater-than-expected proportion of Hb M-Kankakee results from preferential association of the electronegative β-globin chains with the M-globin chains that are more electropositive than normal -globin chains.
Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM
Vij, Ravi , Wang, Michael , Kukreti, Vishal , McDonagh, Kevin T., Alsina, Melissa , Belch, Andrew R. , Gabrail, Nashat , Matous, Jeffrey, Vesole, David H., Wear, Sandra, Kunkel, Lori, Stewart, Keith, Kaufman, Jonathan L. , Jakubowiak, Andrzej , Jagannath, Sundar , Bahlis, Nizar Jacques , Reu, Frederic J. , Orlowski, Robert Z. , Wong, Alvin , Lee, Peter P.

Mayo Clinic

Blood | October 14, 2019 | Volume: 118 | Issue: 21 | Pages: 813-813

10.1182/blood.v118.21.813.813 Get It

Abstract Abstract 813FN2 Introduction: Carfilzomib is a next-generation proteasome inhibitor that selectively and irreversibly binds to its target, resulting in sustained inhibition absent of off-target effects relative to bortezomib. Carfilzomib has demonstrated durable anti-tumor activity and an acceptable tolerability profile in patients with multiple myeloma (MM). Final results will be presented for the bortezomib-naïve group of PX-171-004, a phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MM. Herein we report the most recent data analysis available at time of abstract submission. Updated final results for the bortezomib-naïve group of PX-171-004, including OS data, will be presented at the meeting. Methods: Patients received either 20 mg/m2 for all treatment cycles (Cohort 1) or a stepped-up dose-escalating regimen of 20 mg/m2 for Cycle 1 and 27 mg/m2 for all treatment cycles thereafter (Cohort 2). Carfilzomib was administered over 2–10 minutes on Days 1, 2, 8, 9, 15, and 16 of every 28-day cycle, for a maximum of 12 cycles. The primary endpoint was the best overall response rate (ORR; [CR + VGPR + PR]) determined according to the IMWG Uniform Response Criteria. Secondary endpoints included the clinical benefit response rate (CBR; [ORR + MR per EBMT criteria]), progression-free survival (PFS), time to progression (TTP), duration of response (DOR), OS, and safety. The result of efficacy analysis from disease assessment by the Independent Review Committee is presented in this abstract. Results: 127 of 129 enrolled bortezomib-naïve patients were evaluable for response. Prior therapies included thalidomide (59%), lenalidomide (59%), alkylating agents (81%), and stem cell transplant (73%). Patients had received a median of 2 prior regimens (1 in 54 patients, 2 in 40 patients, 3 in 28 patients, and ≥4 in 7 patients). 84 patients (65%) were disease refractory to their most recent therapy, defined as ≤25% response or progression during or within 60 days after completion of therapy. The median duration of carfilzomib treatment is 7 cycles (range 1−12) in Cohort 1; 8 patients were receiving drug as of February 2011 in Cohort 2 with a median treatment of 6.5 cycles (range 1−13) at that time. Best ORR was 42% in Cohort 1 and 52% in Cohort 2. Median TTP was 8.3 months and median DOR was 13.1 months in Cohort 1. The median TTP and DOR for Cohort 2 have not been reached at the time of this interim analysis; the lower bound of the 95% CI for the median TTP was 10.2 months, and 84% were estimated to have DOR ≥1 year at the time of data cutoff. Higher response rates for Cohort 2 compared with Cohort 1 do not appear to be associated with higher toxicities. Patients with unfavorable cytogenetic characteristics (≥1 abnormality) per mSMART criteria had an ORR of 37% and CBR of 42% compared with 50% and 65%, respectively, for patients with no abnormality. The most common treatment-emergent adverse events (AEs), regardless of relationship to carfilzomib in Cohorts 1 and 2, respectively, were fatigue (71%, 54%), nausea (54%, 43%), anemia (46%, 37%), and dyspnea (49%, 33%). These were primarily ≤Grade 2 in severity. The most common Grade 3/4 AEs were anemia (15%), lymphopenia (15%), thrombocytopenia (13%), pneumonia (12%) and neutropenia (12%). Treatment-emergent peripheral neuropathy (PN) was mild and infrequent (16%). Only 1 case of Grade 3 PN (0.8%) was observed. Overall, 38 patients (30%) completed 12 cycles and 22 of these patients continued to receive carfilzomib therapy under a safety extension protocol (PX-171-010), an ongoing, multicenter, open-label phase 2 study to monitor long-term use of single-agent carfilzomib. Conclusions: To date we have seen robust and durable single-agent activity for carfilzomib in bortezomib-naïve patients with relapsed and often refractory MM with an ORR of 42−52% and a CBR of 59−63% from 2 separate dose cohorts in a population wherein 92% received an immunomodulatry drug and 73% had undergone an autologous stem cell transplant previously. These data are suggestive of a dose–response relationship and are being further evaluated in the exploratory phase 1b/2 study PX-171-007. Carfilzomib was associated with minimal PN and excellent long-term tolerability, with nearly one-third of patients completing 12 cycles and 22 of these continuing treatment beyond 1 year in the extension protocol PX-171-010. Disclosures: Vij: Onyx Pharmaceuticals: Consultancy, Research Funding; Celgene: Research Funding, Speakers Bureau; Millennium: Speakers Bureau. Kaufman:Millenium: Consultancy; Onyx Pharmaceuticals: Consultancy; Novartis: Consultancy; Keryx: Consultancy; Merck: Research Funding; Celgene: Research Funding. Jakubowiak:Ortho Biotech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau; Millennium Pharmaceuticals, Inc.: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Onyx Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Exelixis: Consultancy, Honoraria. Wang:Onyx Pharmaceuticals: Research Funding. Jagannath:Millennium: Honoraria; Celgene: Honoraria; Onyx Pharmaceuticals: Honoraria; Merck: Honoraria; OrthoBiotec.Imedex: Membership on an entity's Board of Directors or advisory committees; Medicom World Wide: Membership on an entity's Board of Directors or advisory committees; Optum Health Education: Membership on an entity's Board of Directors or advisory committees; PER Group: Membership on an entity's Board of Directors or advisory committees. Kukreti:Celgene: Honoraria. Alsina:Millennium: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Allergan: Research Funding. Belch:Celgene: Research Funding; Onyx: Research Funding. Gabrail:Millennium: Research Funding. Matous:Celgene: Speakers Bureau; Millenium: Speakers Bureau; Cephalon: Speakers Bureau. Vesole:Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Millennium: Speakers Bureau. Orlowski:Onyx Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees. Kunkel:VLST biothech: Consultancy; Threshold: Consultancy; Onyx Pharmaceuticals: Consultancy. Wong:Onyx Pharmaceuticals: Employment, Equity Ownership. Stewart:Celgene: Consultancy, Research Funding; Millennium: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Onyx Pharmaceuticals: Consultancy, Research Funding.
Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies
Kelly, Kevin R. , Padmanabhan, Swaminathan, Reeder, Craig B. , McDonagh, Kevin T., Zhou, Xiaofei , Danaee, Hadi , Xiao, Hugh, Benaim, Ely , Shea, Thomas C., Padmanabhan, Swaminathan, Goy, Andre Henri , Berdeja, Jesús G.

Mayo Clinic

Blood | October 12, 2019 | Volume: 118 | Issue: 21 | Pages: 2477-2477

10.1182/blood.v118.21.2477.2477 Get It

Abstract Abstract 2477 Background: Aurora A kinase (AAK) is a key mitotic regulator, inhibition of which results in mitotic spindle defects, mitotic delay, and apoptosis. AAK is amplified or overexpressed in a number of heme-lymphatic malignancies. This phase 1, multicenter study (NCT00697346) is the first to assess safety, tolerability, and pharmacokinetics (PK) of the investigational AAK inhibitor alisertib (MLN8237) in patients with advanced hematologic malignancies. Methods: Patients aged ≥18 years with relapsed/refractory hematologic malignancy, confirmed radiographically or clinically evaluable disease, and ECOG performance status 0–2, were eligible for inclusion. Patients with prior allogeneic transplant were excluded; there was no restriction on the number of prior therapies. Patients received escalating doses (standard 3+3 design) of alisertib as either a powder-in-capsule (PIC) or enteric coated tablet (ECT) formulation. Alisertib PIC was administered as a twice-daily (BID) loading dose on Day 1, then once daily (QD) on Days 2–14 or 2–21, followed by 14 or 7 days' rest, respectively, in 28-day cycles. Alisertib ECT administration followed the same scheme in the first dose group, and subsequent groups received divided (BID) doses for 7 days plus 14 days' rest in 21-day cycles. Endpoints included maximum tolerated dose (MTD), dose-limiting toxicity (DLT), safety, PK, and response. Results: 55 patients were included (PIC n=28, ECT n=27); median age was 61 years (range 27–82), 42% had prior ASCT, and 78% had received ≥3 prior therapies. 60% of patients had non-Hodgkin's lymphoma, 35% multiple myeloma, and 5% chronic lymphocytic leukemia/small lymphocytic lymphoma. Patients received a median of 2 cycles (range 1–14); 8 patients are ongoing. The MTD on the alisertib PIC 14-day + 14 days' rest schedule was 45 mg QD, established following occurrence of DLTs in four patients at higher dose levels: Gr 4 thrombocytopenia, Gr 4 neutropenia (65 mg QD); Gr 3 febrile neutropenia, Gr 4 thrombocytopenia (90 mg QD). In patients receiving alisertib ECT, the MTD was determined as 50 mg BID on a 7-day + 14 days' rest schedule; four DLTs were observed in three patients: at 40 mg QD for 14 days, one patient had Gr 4 febrile neutropenia, and one patient had Gr 4 bullous dermatitis and Gr 4 neutropenia; at 50 mg BID for 7 days, one of nine patients had Gr 4 neutropenia. The most common drug-related adverse events (AEs) were neutropenia (PIC 46%, ECT 63%), thrombocytopenia (39%, 41%), and diarrhea (29%, 41%); most common Gr ≥3 drug-related AEs were neutropenia (PIC 36%, ECT 52%), thrombocytopenia (29%, 26%), and anemia (14%, 26%). 24 patients (PIC n=12, ECT n=12) had serious AEs; the most common was febrile neutropenia (PIC n=1, ECT n=4). Tolerability appeared generally similar between the PIC and ECT formulations. Six patients (PIC n=3, ECT n=3) died during the study (PIC: renal failure, airway obstruction, progressive large cell lymphoma; ECT: progressive myeloma [n=2], hypercalcemia); no deaths were considered to be related to alisertib. Alisertib absorption was rapid with an overall median Tmax of 2 hours. The overall mean terminal half-life following multiple dosing was 19 hours. The mean peak/trough (P/T) ratio was 5 following QD dosing as PIC. The mean accumulation ratio and P/T ratio were 2.5 and 2.1, respectively, following BID dosing as ECT. At data cut-off (29 March, 2011), 42 patients were evaluable for response. Antitumor activity was observed in five patients (PIC n=3, ECT n=2) who had partial responses; 11 patients had a best response of stable disease (PIC n=6, ECT n=5) and 26 had progressive disease (PIC n=14, ECT n=12). Seven patients received ≥5 cycles of therapy, including one patient (PIC group; post-transplant grade 3B follicular lymphoma) with resolution of B symptoms who received alisertib for >1 year. Conclusions: The MTDs of the PIC and ECT formulations of alisertib are 45 mg QD for 14 days (+14 days' rest) and 50 mg BID for 7 days (+ 14 days' rest), respectively, in patients with advanced, non-leukemic hematologic malignancies. AEs were generally manageable and were consistent with inhibition of AAK in highly proliferative tissues (gastrointestinal and hematologic AEs). Current data support further investigation and expansion at the MTDs is ongoing. Data from PK, safety, and tolerability collectively support the progression of ECT formulation at 50 mg BID for 7 days in a 21-day cycle into phase 2 development. Disclosures: Off Label Use: Investigational agent in clinical development for the treatment of advanced hematologic malignancies and solid tumors. Goy:Millennium Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GSK: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genentech: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Reeder:Millennium Pharmaceuticals, Inc.: Institutional research funding; Novartis: Institutional research funding; Celgene: Institutional research funding. Zhou:Millennium Pharmaceuticals, Inc.: Employment. Danaee:Millennium Pharmaceuticals, Inc.: Employment. Xiao:Millennium Pharmaceuticals, Inc.: Employment. Benaim:Millennium Pharmaceuticals, Inc.: Employment, Equity Ownership. Shea:Millennium Pharmaceuticals, Inc.: Consultancy, Research Funding.